EOS - Excellence of Science (Belgian federal Program)
Organisme subsidiant :
F.R.S.-FNRS - Fonds de la Recherche Scientifique FWO - Fonds Wetenschappelijk Onderzoek Vlaanderen
Subventionnement (détails) :
Support statement: This work was supported by the EOS (Excellence of Science) Belgian Federal Program, grant: EOS 30565447. Funding information for this article has been deposited with the Crossref Funder Registry.
Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-2128.
Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2163-2196.
Bateman ED, Reddel HK, van Zyl-Smit RN, et al. The asthma-COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases? Lancet Respir Med 2015; 3: 719-728.
Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J 2016; 47: 410-419.
Martin RJ, Bel EH, Pavord ID, et al. Defining severe obstructive lung disease in the biologic era: an endotype-based approach. Eur Respir J 2019; 54: 1900108.
Agusti A, Bafadhel M, Beasley R, et al. Precision medicine in airway diseases: moving to clinical practice. Eur Respir J 2017; 50: 1701655.
Louis R, Roche N. Personalised medicine: are we ready? Eur Respir Rev 2017; 26: 170088.
Teague WG, Phillips BR, Fahy JV, et al. Baseline features of the severe asthma research program (SARP III) cohort: differences with age. J Allergy Clin Immunol Pract 2018; 6: 545-554.
Vestbo J, Agusti A, Wouters EF, et al. Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. Am J Respir Crit Care Med 2014; 189: 1022-1030.
Reddel HK, Gerhardsson D, Agusti VA, et al. Prospective observational study in patients with obstructive lung disease: NOVELTY design. ERJ Open Res 2019; 5: 00036-2018.
Reddel HK, Vestbo J, Agustí A, et al. Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort. Eur Respir J 2021; 58: 2003927.
Herland K, Akselsen JP, Skjonsberg OH, et al. How representative are clinical study patients with asthma or COPD for a larger “real life” population of patients with obstructive lung disease? Respir Med 2005; 99: 11-19.
Appleton SL, Adams RJ, Wilson DH, et al. Spirometric criteria for asthma: adding further evidence to the debate. J Allergy Clin Immunol 2005; 116: 976-982.
Bousquet J, Jeffery PK, Busse WW, et al. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000; 161: 1720-1745.
Louis R, Bougard N, Guissard F, et al. Bronchodilation test with inhaled salbutamol versus bronchial methacholine challenge to make an asthma diagnosis: do they provide the same information? J Allergy Clin Immunol Pract 2020; 8: 618-625.
Nair P, Martin JG, Cockcroft DC, et al. Airway hyperresponsiveness in asthma: measurement and clinical relevance. J Allergy Clin Immunol Pract 2017; 5: 649-659.
Aaron SD, Boulet LP, Reddel HK, et al. Underdiagnosis and overdiagnosis of asthma. Am J Respir Crit Care Med 2018; 198: 1012-1020.
Bourdin A, Bjermer L, Brightling C, et al. ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions. Eur Respir J 2019; 54: 1900900.
Louis R, Ziant S, Duchesnes C, et al. Exacerbations in asthma and chronic obstructive pulmonary disease (COPD). Survey on the criteria of pescription of systemic corticoids and antibiotics by general practicioners and chest physicians. Rev Med Liege 2018; 73: 570-574.
Schleich FN, Chevremont A, Paulus V, et al. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. Eur Respir J 2014; 44: 97-108.
Hastie AT, Moore WC, Li H, et al. Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. J Allergy Clin Immunol 2013; 132: 72-80.
Pavord ID, Holliday M, Reddel HK, et al. Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial. Lancet Respir Med 2020; 8: 671-680.
van Bragt JJMH, Adcock IM, Bel EHD, et al. Characteristics and treatment regimens across ERS SHARP severe asthma registries. Eur Respir J 2020; 55: 1901163.
Demarche S, Schleich F, Henket M, et al. Step-down of inhaled corticosteroids in non-eosinophilic asthma: a prospective trial in real life. Clin Exp Allergy 2018; 48: 525-535.
Demarche SF, Schleich FN, Henket MA, et al. Effectiveness of inhaled corticosteroids in real life on clinical outcomes, sputum cells and systemic inflammation in asthmatics: a retrospective cohort study in a secondary care centre. BMJ Open 2017; 7: e018186.
Frix AN, Schleich F, Paulus V, et al. Effectiveness of omalizumab on patient reported outcomes, lung function, and inflammatory markers in severe allergic asthma. Biochem Pharmacol 2020; 179: 113944.
Louis R, Djukanovic R. Is the neutrophil a worthy target in severe asthma and chronic obstructive pulmonary disease? Clin Exp Allergy 2006; 36: 563-567.
O'Byrne PM, Metev H, Puu M, et al. Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2016; 4: 797-806.
Porsbjerg CM, Sverrild A, Lloyd CM, et al. Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics. Eur Respir J 2020; 56: 2000260.
Peters MC, Mauger D, Ross KR, et al. Evidence for exacerbation-prone asthma and predictive biomarkers of exacerbation frequency. Am J Respir Crit Care Med 2020; 202: 973-982.
Corhay JL, Dang DN, Van CH, et al. Pulmonary rehabilitation and COPD: providing patients a good environment for optimizing therapy. Int J Chron Obstruct Pulmon Dis 2014; 9: 27-39.
